Drug Trial Radar · NCT06953076
Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study
Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
111
Planned (sponsor's estimate)
Start
May 2, 2025
Primary completion
May 2, 2026
Study completion May 2, 2027
Sponsor
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 1, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery. Ultrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.
Conditions
- Uterine Bleeding
- Uterine Leiomyomas
- Uterine Hemorrhage
- Uterine Neoplasms
Interventions
Relugolix/estradiol/norethisterone acetateDrug
Oral therapy administered to patients with symptomatic uterine fibroids presenting with abnormal uterine bleeding
Primary outcomes
What the sponsor says the trial is designed to measure.
- To observe modifications in the volume of the myometrial lesion during treatment with relugolix/estradiol/norethisteroneTime frame: at baseline, and after 3 months, 6 months, and 12 months from treatment initiation
- To observe the ultrasound features of myometrial lesions during treatment with relugolix/estradiol/norethisteroneTime frame: at baseline, and after 3 months, 6 months, and 12 months from treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC GINECOLOGIA ONCOLOGICA
Roma, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.